🇺🇸 FDA
Pipeline program

PIPE-791 Dose A

CTX-791-201

Phase 2 small_molecule active

Quick answer

PIPE-791 Dose A for Idiopathic Pulmonary Fibrosis is a Phase 2 program (small_molecule) at Contineum Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Contineum Therapeutics
Indication
Idiopathic Pulmonary Fibrosis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials